Andere Sprachen Ainos, Inc.

Aktien

A3E2F6

US00902F3038

AIMD

Verzögert Nasdaq Andere Börsenplätze 19:48:12 09.05.2024			% 5 Tage	% 1. Jan.
1,05 ^USD	+0,01 %		+0,98 %	-48,77 %

11.03.	Händler erwarten Inflationsbericht, US-Aktien eröffnen schwächer an der Wall Street	MT
11.03.	Top-Absteiger vorbörslich	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	19.03.
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer	15.03.
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	11.03.
Top Premarket Decliners	11.03.
Ainos : Reports Full Year 2023 Financial Results - Form 8-K	08.03.
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08.03.
Top Premarket Gainers	08.03.
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial	05.02.
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms	05.02.
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th	01.02.
Ainos Announces $1.75 Million Follow-On Funding	25.01.
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation	12.01.
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05.01.
Ainos Regains Compliance With Nasdaq Listing Rule	02.01.
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell	26.12.
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary	22.12.
Ainos, Inc. Announces Stock Consolidation	13.12.
Ainos : Private Placement - Form 8-K	24.11.
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data	21.11.
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA	21.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ainos, Inc.

Aktien

A3E2F6

US00902F3038

AIMD

Andere Sprachen

Filter